Bruker Analysts Cut Their Forecasts After Q3 Results
Bruker Analysts Cut Their Forecasts After Q3 Results
Bruker shares fell 1.9% to trade at $60.15 on Wednesday.Bruker Corporation (NASDAQ:BRKR) posted better-than-expected third-quarter results, but lowered its FY24 guidance on Tuesday.
Bruker公司（納斯達克：BRKR）在週二發佈了好於預期的第三季度業績，但下調了2024財年的指引。
Bruker posted adjusted earnings of 60 cents per share, beating market estimates of 59 cents per share. The company posted sales of $864.400 million versus expectations of $859.384 million.
Bruker發佈了每股60美分的調整後收益，超過市場預期的每股59美分。該公司的銷售額爲86440萬美元，好於預期的85938.4萬美元。
Frank H. Laukien, Bruker's President and CEO, commented, "Despite biopharma and China recovery delays, orders for our differentiated post-genomic, multiomics, cleantech, semicon and diagnostics solutions are gradually improving, with upper mid-single digit BSI organic bookings growth in Q3 year-over-year. However, nascent biopharma and China recoveries will not benefit our fiscal year 2024 anymore, and accordingly we are lowering our FY2024 guidance. Integrating and improving our strategic acquisitions is making good progress and will further accelerate Bruker's remarkable transformation. We are confident in our ability to drive above-market organic revenue growth with significant margin expansion in 2025."
Bruker的總裁兼首席執行官Frank H. Laukien評論說：「儘管生物製藥和中國的復甦延遲，但我們不同凡響的基因組後期、多組學、清潔技術、半導體和診斷解決方案的訂單逐漸改善，在第三季度同比實現了上中單位數的BSI有機預訂增長。然而，新興的生物製藥和中國的復甦將不再使我們受益於2024財年，因此我們正在下調2024財年的指引。整合和改進我們的戰略收購正在取得良好進展，將進一步加速Bruker的顯著轉型。我們有信心能夠在2025年實現高於市場的有機營收增長，並實現重大的利潤率擴張。」
Bruker shares fell 1.9% to trade at $60.15 on Wednesday.
週三，Bruker股價下跌1.9%，報60.15美元交易。
These analysts made changes to their price targets on Bruker following earnings announcement.
這些分析師在Bruker發佈收益公告後調整了他們的價格目標。
- Barclays analyst Terence Malone maintained Bruker with an Overweight and lowered the price target from $75 to $69.
- Wells Fargo analyst Brandon Couillard maintained Bruker with an Overweight and lowered the price target from $78 to $75.
- TD Cowen analyst Dan Brennan maintained the stock with a Hold and lowered the price target from $72 to $70.
- Citigroup analyst Patrick Donnelly maintained Bruker with a Buy and cut the price target from $80 to $75.
- 巴克萊銀行分析師Terence Malone維持了對Bruker的超配評級，並將價格目標從75美元下調至69美元。
- 富國銀行分析師Brandon Couillard維持了對Bruker的超配評級，並將價格目標從78美元下調至75美元。
- TD Cowen分析師Dan Brennan維持了對該股的持有評級，並將價格目標從72美元下調至70美元。
- 花旗集團分析師帕特里克·唐納利維持對Bruker的買入評級，並將目標股價從80美元降至75美元。
Considering buying BRKR stock? Here's what analysts think:
考慮購買BRKR股票嗎？這是分析師的看法：
Read More:
閱讀更多：
- Amazon, Disney, DuPont, Leidos And A Financial Stock On CNBC's 'Final Trades'
- 亞馬遜、迪士尼、杜邦、leidos和CNBC的「最終交易」中的一隻金融股
譯文內容由第三人軟體翻譯。
